Core Scientific Inc vs Tilray Brands Inc — how do they compare? Core Scientific Inc trades at $15.3 (market cap $4.94B), while Tilray Brands Inc trades at $3.5 (market cap $530.54M). The key difference: Core Scientific Inc is far larger — about 9.3× Tilray Brands Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| CORZ | TLRY | |
|---|---|---|
Market Cap | $4.94B | $530.54M |
Volume | 15,630,800 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $29.16 | $21.00 |
52-Week Low | $13.57 | $3.57 |
Typical Hold Time | 20 Days | — |
Enterprise Value | $7.46B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.25, down 4.36% today amid a bearish technical trend. The stock shows weak fundamentals with a net loss of $288.62 million in 2025 and negative profit margins, though revenue is projected to grow to $440 million in 2026. Analyst sentiment remains strongly bullish with an 86% buy rating and a $32.75 consensus price target, but recent earnings misses and high cash burn pose significant risks.
The outlook is mixed: strong analyst support and insider buying suggest confidence in the AI data center strategy, but persistent losses, negative cash flow, and competitive pressures require careful monitoring. The stock's current price near support levels offers potential upside if execution improves, yet volatility and operational challenges present substantial downside risk.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →